Advertisement

Mammakarzinom bei der alten und geriatrischen Patientin

  • Nadia Harbeck
  • Rachel Würstlein
  • Maximiliane Burgmann
Chapter
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Die moderne Mammakarzinomtherapie basiert auf den Säulen lokoregionäre und systemische Therapie, wobei die individuellen Therapiekonzepte idealerweise im interdisziplinären Tumorboard festgelegt werden. In Deutschland bilden die jährlich aktualisierten AGO-Empfehlungen die Grundlage des Vorgehens bei älteren Patientinnen. Generell ist das kalendarische Alter allein kein ausreichender Grund, auf eine leitliniengerechte Therapie zu verzichten. Bei der Therapieplanung sollten die Therapieziele berücksichtigt werden. Während das frühe Mammakarzinom ohne Fernmetastasen mit kurativer Intention behandelt wird, stehen bei der metastasierten Erkrankung Symptomkontrolle und Erhalt der Lebensqualität im Vordergrund. Da sich individuelle Komorbiditäten und Lebenserwartung bei älteren Patientinnen sehr unterscheiden können, sind generalisierte Therapieempfehlungen schwierig. Eine individualisierte Therapieführung ist dennoch evidenzbasiert möglich.

Literatur

  1. Aapro M (2011) SIOG (International Society of Geriatric Oncology) recommendations for anthracycline use in the elderly. Hematol Rep 3(3s), e6.  https://doi.org/10.4081/hr.2011.s3.e6CrossRefPubMedPubMedCentralGoogle Scholar
  2. AGO-Kommission „Mamma“ (2017) Empfehlungen 2017 für die Behandlung des primären und des metastasierten Mammakarzinoms: https://www.ago-online.de/de/infothek-fuer-aerzte/kommissionen/kommission-mamma/. Zugegriffen am 15.06.2017
  3. Aprile G, Ferrari L, Fontanella C, Puglisi F (2013) Bevacizumab in older patients with advanced colorectal or breast cancer. Crit Rev Oncol Hematol 87(1):41–54.  https://doi.org/10.1016/j.critrevonc.2012.11.006CrossRefPubMedGoogle Scholar
  4. Bachelot T, Pérez-Alcántara F, Ciruelos E, Peretz-Yablonski T, Schneeweiss A, Easton V, Lindegger N, Restuccia E, Miles D (2016) Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (PERUSE). SABCS 2016, P4-21-04Google Scholar
  5. Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, Breast Cancer Groups et al (2015) Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol 16(1):47–56.  https://doi.org/10.1016/S1470-2045(14)71156-8
  6. Bastiaannet E, Liefers GJ, de Craen AJ, Kuppen PJ, van de Water W, Portielje JE, Westendorp RG et al (2010) Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients. Breast Cancer Res Treat 124(3):801–807.  https://doi.org/10.1007/s10549-010-0898-8
  7. Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, Audisio R et al (2012) Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 13(4):e148–e160.  https://doi.org/10.1016/S1470-2045(11)70383-7
  8. Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, O’Shaughnessy J et al (2012) Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 30(21):2585–2592.  https://doi.org/10.1200/JCO.2011.35.6725
  9. Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA, Wolmark N et al (2017) Anthracyclines in early breast cancer: the ABC Trials-USOR 06–090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol JCO2016714147.  https://doi.org/10.1200/JCO.2016.71.4147
  10. Boer K (2005) Effective treatment strategy in elderly breast cancer patients. Orv Hetil 146(1):15–21PubMedGoogle Scholar
  11. Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schafer P, Vlastos G et al (2003) Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 21(19): 3580–3587.  https://doi.org/10.1200/JCO.2003.02.046
  12. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Herceptin Adjuvant Trial Study T et al (2017) 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389(10075):1195–1205.  https://doi.org/10.1016/S0140-6736(16)32616-2
  13. Campbell NL, Boustani MA, Skopelja EN, Gao S, Unverzagt FW, Murray MD (2012) Medication adherence in older adults with cognitive impairment: a systematic evidence-based review. Am J Geriatr Pharmacother 10(3):165–177.  https://doi.org/10.1016/j.amjopharm.2012.04.004CrossRefPubMedGoogle Scholar
  14. Cappellani A, Di Vita M, Zanghi A, Cavallaro A, Piccolo G, Majorana M, Berretta M et al (2013) Prognostic factors in elderly patients with breast cancer. BMC Surg 13(Suppl 2):S2.  https://doi.org/10.1186/1471-2482-13-S2-S2
  15. Chesney TR, Yin JX, Rajaee N, Tricco AC, Fyles AW, Acuna SA, Scheer AS (2017) Tamoxifen with radiotherapy compared with Tamoxifen alone in elderly women with early-stage breast cancer treated with breast conserving surgery: a systematic review and meta-analysis. Radiother Oncol 123(1):1–9.  https://doi.org/10.1016/j.radonc.2017.02.019CrossRefPubMedGoogle Scholar
  16. Christiansen P, Bjerre K, Ejlertsen B, Jensen MB, Rasmussen BB, Laenkholm AV, Danish Breast Cancer Cooperative G et al (2011) Mortality rates among early-stage hormone receptor-positive breast cancer patients: a population-based cohort study in Denmark. J Natl Cancer Inst 103(18):1363–1372.  https://doi.org/10.1093/jnci/djr299
  17. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Panel M et al (2015) Tailoring therapies – improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26(8):1533–1546.  https://doi.org/10.1093/annonc/mdv221
  18. Crivellari D, Spazzapan S, Lombardi D, Berretta M, Magri MD, Sorio R, Veronesi A et al (2003) Treatment of older breast cancer patients with high recurrence risk. Crit Rev Oncol Hematol 46(3):241–246Google Scholar
  19. Crivellari et al (2013) Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a „standard chemotherapy regimen“: the CASA randomized trial. BreastGoogle Scholar
  20. Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Gruppo Italiano Mammella i et al (2015) Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial. Lancet 385(9980):1863–1872.  https://doi.org/10.1016/S0140-6736(14)62048-1
  21. Early Breast Cancer Trialists’ Collaborative (Ebctcg) G, Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Gray R et al (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386(10001):1353–1361.  https://doi.org/10.1016/S0140-6736(15)60908-4
  22. Ebctcg G, Darby S, McGale P, Correa C, Taylor C, Arriagada R, Peto R et al (2011a) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804):1707–1716.  https://doi.org/10.1016/S0140-6736(11)61629-2
  23. Ebctcg G, Davies C, Godwin J, Gray R, Clarke M, Cutter D, Peto R et al (2011b) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784.  https://doi.org/10.1016/S0140-6736(11)60993-8
  24. Ebctcg, McGale P, Taylor C, Correa C, Cutter D, Duane F, Darby S et al (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935):2127–2135.  https://doi.org/10.1016/S0140-6736(14)60488-8
  25. Ebctcg G, Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Gray R et al (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386(10001):1341–1352.  https://doi.org/10.1016/S0140-6736(15)61074-1
  26. Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, Mackey JR et al (2011) Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 29(29):3877–3884.  https://doi.org/10.1200/JCO.2010.28.5437
  27. Gaertner J, Wuerstlein R, Ostgathe C, Mallmann P, Harbeck N, Voltz R (2011) Facilitating early integration of palliative care into breast cancer therapy. Promoting disease-specific guidelines. Breast Care (Basel) 6(3):240–244.  https://doi.org/10.1159/000329007CrossRefGoogle Scholar
  28. Gluz O, Nitz U, Liedtke C, Christgen M, Sotlar K, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Bangemann N, Lindner C, Kuemmel S, Clemens M, Potenberg J, Staib P, Kohls A, Pelz E, Kates RE, Wuerstlein R, Kreipe HH, Harbeck N (2015) Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple- negative breast cancer: WSG-ADAPT TN randomized phase II trial. SABCS 2015, Abstract S6–07Google Scholar
  29. Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Colorectal Cancer Study G et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386(9992):433–443.  https://doi.org/10.1016/S0140-6736(15)60995-3
  30. Harbeck N, Gnant M (2017) Breast cancer. Lancet 389(10074):1134–1150.  https://doi.org/10.1016/S0140-6736(16)31891-8CrossRefPubMedGoogle Scholar
  31. Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Shapiro CL et al (2017) Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA 317(1):48–58.  https://doi.org/10.1001/jama.2016.19425
  32. Inwald EC, Ortmann O, Koller M, Zeman F, Hofstadter F, Evert M, Klinkhammer-Schalke M et al (2017) Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology. Breast Cancer Res Treat 163(1):119–130.  https://doi.org/10.1007/s10549-017-4151-6
  33. Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Savin MA et al (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol 27(8):1177–1183.  https://doi.org/10.1200/JCO.2008.18.4028
  34. Kolberg HC, Aktas B, Liedtke C (2017) Clinical utility of neoadjuvant endocrine therapy for hormone receptor positive breast cancer. Rev Recent Clin TrialsGoogle Scholar
  35. Lichtman SM, Cirrincione CT, Hurria A, Jatoi A, Theodoulou M, Wolff AC, Muss HB et al (2016) Effect of pretreatment renal function on treatment and clinical outcomes in the adjuvant treatment of older women with breast cancer: alliance A171201, an ancillary study of CALGB/CTSU 49907. J Clin Oncol 34(7):699–705.  https://doi.org/10.1200/JCO.2015.62.6341
  36. Livi L, Paiar F, Saieva C, Simontacchi G, Nori J, Sanchez L, Biti G et al (2006) Breast cancer in the elderly: treatment of 1500 patients. Breast J 12(4):353–359.  https://doi.org/10.1111/j.1075-122X.2006.00275.x
  37. Loibl S, von Minckwitz G, Harbeck N, Janni W, Elling D, Kaufmann M, Kummel S et al (2008) Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials. Breast Cancer Res 10(5):R77.  https://doi.org/10.1186/bcr2144
  38. Mandelblatt J (2006) Treating breast cancer: the age old dilemma of old age. J Clin Oncol 24(27):4369–4370.  https://doi.org/10.1200/JCO.2006.07.4302CrossRefPubMedGoogle Scholar
  39. Mandelblatt JS, Kerner JF, Hadley J, Hwang YT, Eggert L, Johnson LE, Options et al (2002) Variations in breast carcinoma treatment in older medicare beneficiaries: is it black or white. Cancer 95(7):1401–1414.  https://doi.org/10.1002/cncr.10825
  40. Martin M, Loibl S, von Minckwitz G, Morales S, Martinez N, Guerrero A, De la Haba-Rodriguez JR et al (2015) Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. J Clin Oncol 33(9):1045–1052.  https://doi.org/10.1200/JCO.2014.57.2388
  41. Matuschek C, Bolke E, Haussmann J, Mohrmann S, Nestle-Kramling C, Gerber PA, Budach W et al (2017) The benefit of adjuvant radiotherapy after breast conserving surgery in older patients with low risk breast cancer- a meta-analysis of randomized trials. Radiat Oncol 12(1):60.  https://doi.org/10.1186/s13014-017-0796-x
  42. Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer EP, Goldhirsch A et al (2015) Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1–98 trial. J Clin Oncol 33(25):2772–2779.  https://doi.org/10.1200/JCO.2015.60.8133
  43. Miles D, Baselga J, Amadori D, Sunpaweravong P, Semiglazov V, Knott A, Swain SM et al (2013) Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Res Treat 142(1): 89–99.  https://doi.org/10.1007/s10549-013-2710-z
  44. Minckwitz G von, Reimer T, Potenberg J, Conrad B, Schürer U, Eidtmann H, Just M, Paepke S, Stickeler E, Heinrich G, Untch M, Moebus V, Thomssen C, Jackisch C, Huober J, Loibl S, Nekljudova V, Nitz U (2014) The phase III ICE study: Adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. SABCS 2014, Oral presentation S3–04Google Scholar
  45. Minckwitz von et al (2015) A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).l, CancerGoogle Scholar
  46. Mislang AR, Biganzoli L (2015) Adjuvant systemic therapy in older breast cancer women: Can we optimize the level of care? Cancers (Basel) 7(3):1191–1214.  https://doi.org/10.3390/cancers7030833CrossRefGoogle Scholar
  47. Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Investigators C et al (2009) Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360(20):2055–2065.  https://doi.org/10.1056/NEJMoa0810266
  48. Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Kuhn W et al (2016) Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol.  https://doi.org/10.1093/annonc/mdw349
  49. Partridge AH, Gelber S, Piccart-Gebhart MJ, Focant F, Scullion M, Holmes E, Gelber RD et al (2013) Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol 31(21):2692–2698.  https://doi.org/10.1200/JCO.2012.44.1956
  50. Perrone F et al (2015) Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Ann Oncol Minckwitz 2014: fehlt mir, folgtGoogle Scholar
  51. Repetto L, Fratino L, Audisio RA, Venturino A, Gianni W, Vercelli M, Zagonel V et al (2002) Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 20(2): 494–502.  https://doi.org/10.1200/JCO.2002.20.2.494
  52. Robert-Koch-Institut (2010) Verbreitung von Krebserkrankungen in Deutschland, Entwicklung der Prävalenzen zwischen 1990 und 2010; Eine Veröffentlichung des Zentrums für Krebsregisterdaten am RKIGoogle Scholar
  53. Rugo HS, Turner N, Finn RS, Joy AA, Verma S, Harbeck N, Moulder S, Masuda N, Im Y-H, Zhang K, Kim S, Sun W, Schnell P, Huang-Bartlett C, Slamon D (2016) Palbociclib in combination with endocrine therapy in treatment-naive and previously treated elderly women with HR+, HER2 advanced breast cancer: a pooled analysis from randomized phase 2 and 3 studies. SABCS 2016, Abstract P4-22-03Google Scholar
  54. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Cortes J et al (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24(9):2278–2284.  https://doi.org/10.1093/annonc/mdt182
  55. Sharma P, Lopez-Tarruella S, Garcia-Saenz JA, Ward C, Connor CS, Gomez HL, Martin M et al (2017) Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: combined analysis of two cohorts. Clin Cancer Res 23(3):649–657.  https://doi.org/10.1158/1078-0432.CCR-16-0162
  56. Sheppard VB, Faul, LA, Luta G, Clapp JD, Yung RL, Wang JH, Mandelblatt JS et al (2014) Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. J Clin Oncol 32(22):2318–2327.  https://doi.org/10.1200/JCO.2013.51.7367
  57. Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O’Regan R, Hudis C et al (2012) Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol 30(33):4071–4076.  https://doi.org/10.1200/JCO.2011.40.6405
  58. Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O’Regan R, Winer EP et al (2014) Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol 32(22):2311–2317.  https://doi.org/10.1200/JCO.2013.53.7142
  59. Silliman RA (2009) When cancer in older adults is undermanaged: the breast cancer story. J Am Geriatr Soc 57(Suppl 2):S259–261.  https://doi.org/10.1111/j.1532-5415.2009.02506.xCrossRefPubMedPubMedCentralGoogle Scholar
  60. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Breast Cancer International Research G et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273–1283.  https://doi.org/10.1056/NEJMoa0910383
  61. Sparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, Davidson NE et al (2015) Long-Term Follow-Up of the E1199 Phase III Trial evaluating the role of taxane and schedule in operable breast cancer. J Clin Oncol 33(21):2353–2360.  https://doi.org/10.1200/JCO.2015.60.9271
  62. Statistisches Bundesamt (2010) Todesursachen in Deutschland; Gesundheitsberichterstattung des Bundes, www.gbe-bund.de. Zugegriffen am 15.06.2017
  63. Statistisches Bundesamt (Destatis) (2011) Ältere Menschen in Deutschland und in der EU, www.destatis.de. Zugegriffen am 15.06.2017
  64. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Braun A et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132–5139.  https://doi.org/10.1200/JCO.2010.29.7101
  65. Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Winer EP et al (2015) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372(2):134–141.  https://doi.org/10.1056/NEJMoa1406281
  66. Verkooijen HM, Fioretta GM, Rapiti E, Bonnefoi H, Vlastos G, Kurtz J, Bouchardy C et al (2005) Patients’ refusal of surgery strongly impairs breast cancer survival. Ann Surg 242(2):276–280Google Scholar
  67. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Group ES et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783–1791.  https://doi.org/10.1056/NEJMoa1209124
  68. Water W van de, Markopoulos C, van de Velde CJ, Seynaeve C, Hasenburg A, Rea D, Jones SE et al (2012) Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA 307(6):590–597.  https://doi.org/10.1001/jama.2012.84
  69. Water W van de, Seynaeve C, Bastiaannet E, Markopoulos C, Jones SE, Rea D, Liefers GJ et al (2013) Elderly postmenopausal patients with breast cancer are at increased risk for distant recurrence: a tamoxifen exemestane adjuvant multinational study analysis. Oncologist 18(1):8–13.  https://doi.org/10.1634/theoncologist.2012-0315
  70. Wang J, Kollias J, Boult M, Babidge W, Zorbas HN, Roder D, Maddern G (2010) Patterns of surgical treatment for women with breast cancer in relation to age. Breast J 16(1):60–65.  https://doi.org/10.1111/j.1524-4741.2009.00828.xCrossRefPubMedGoogle Scholar
  71. Wenderlein JM (2012a) Correspondence (letter to the editor): prevalence rises in postmenopausal women. Dtsch Arztebl Int 109(5):80.  https://doi.org/10.3238/arztebl.2012.0080b; reply 81–82PubMedPubMedCentralGoogle Scholar
  72. Wenderlein MJ (2012b) Correspondence (letter to the editor): do not forget estrogen therapy. Dtsch Arztebl Int 109(42):714.  https://doi.org/10.3238/arztebl.2012.0714a; author reply 714PubMedPubMedCentralGoogle Scholar
  73. Yancik R, Ries LA (2004) Cancer in older persons: an international issue in an aging world. Semin Oncol 31(2):128–136CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Nadia Harbeck
    • 1
  • Rachel Würstlein
    • 1
  • Maximiliane Burgmann
    • 1
  1. 1.Brustzentrum der Universität MünchenMünchenDeutschland

Section editors and affiliations

  • Nicolai Härtel
    • 1
  1. 1.Interdisziplinäres TumorzentrumUniversitätsmedizin MannheimMannheimDeutschland

Personalised recommendations